PL435199A1 - Kompozycja bakteriofagów specyficzna wobec bakterii z rodziny Enterobacterlaceae, zwłaszcza Escherichia coli, zastosowanie kompozycji bakteriofagów do leczenia zakażeń wywołanych przez bakterie z rodziny Enterobacterlaceae, zwłaszcza Escherichia coli oraz zastosowanie kompozycji bakteriofagów jako czynnika biokontroli - Google Patents
Kompozycja bakteriofagów specyficzna wobec bakterii z rodziny Enterobacterlaceae, zwłaszcza Escherichia coli, zastosowanie kompozycji bakteriofagów do leczenia zakażeń wywołanych przez bakterie z rodziny Enterobacterlaceae, zwłaszcza Escherichia coli oraz zastosowanie kompozycji bakteriofagów jako czynnika biokontroliInfo
- Publication number
- PL435199A1 PL435199A1 PL435199A PL43519920A PL435199A1 PL 435199 A1 PL435199 A1 PL 435199A1 PL 435199 A PL435199 A PL 435199A PL 43519920 A PL43519920 A PL 43519920A PL 435199 A1 PL435199 A1 PL 435199A1
- Authority
- PL
- Poland
- Prior art keywords
- bacteriophage composition
- escherichia coli
- enterobacterlaceae
- particular escherichia
- bacteriophage
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Wood Science & Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Przedmiotem zgłoszenia jest kompozycja bakteriofagów specyficzna wobec bakterii z rodziny Enterobacteriaceae, zwłaszcza Escherichia coli zdeponowana w Polskiej Kolekcji Mikroorganizmów (PCM) pod numerem depozytowym F/00156. Zgłoszenie obejmuje też zastosowanie kompozycji bakteriofagów do wytwarzania leczniczych preparatów przeciwbakteryjnych służących do zwalczania bakterii z rodziny Enterobacteriaceae.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PL435199A PL240027B1 (pl) | 2020-09-03 | 2020-09-03 | Kompozycja bakteriofagów specyficzna wobec bakterii z rodziny Enterobacteriaceae, zwłaszcza Escherichia coli, zastosowanie kompozycji bakteriofagów w zwalczaniu bakterii z rodziny Enterobacteriaceae, zwłaszcza Escherichia coli oraz zastosowanie kompozycji bakteriofagów jako czynnika biokontroli |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PL435199A PL240027B1 (pl) | 2020-09-03 | 2020-09-03 | Kompozycja bakteriofagów specyficzna wobec bakterii z rodziny Enterobacteriaceae, zwłaszcza Escherichia coli, zastosowanie kompozycji bakteriofagów w zwalczaniu bakterii z rodziny Enterobacteriaceae, zwłaszcza Escherichia coli oraz zastosowanie kompozycji bakteriofagów jako czynnika biokontroli |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| PL435199A1 true PL435199A1 (pl) | 2021-04-06 |
| PL240027B1 PL240027B1 (pl) | 2022-02-07 |
Family
ID=75297950
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL435199A PL240027B1 (pl) | 2020-09-03 | 2020-09-03 | Kompozycja bakteriofagów specyficzna wobec bakterii z rodziny Enterobacteriaceae, zwłaszcza Escherichia coli, zastosowanie kompozycji bakteriofagów w zwalczaniu bakterii z rodziny Enterobacteriaceae, zwłaszcza Escherichia coli oraz zastosowanie kompozycji bakteriofagów jako czynnika biokontroli |
Country Status (1)
| Country | Link |
|---|---|
| PL (1) | PL240027B1 (pl) |
-
2020
- 2020-09-03 PL PL435199A patent/PL240027B1/pl unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PL240027B1 (pl) | 2022-02-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Gonzalez-Barca et al. | Prospective study of 288 episodes of bacteremia in neutropenic cancer patients in a single institution | |
| Gribble et al. | Prospective randomized trial of piperacillin monotherapy versus carboxypenicillin-aminoglycoside combination regimens in the empirical treatment of serious bacterial infections | |
| Aiyegoro et al. | In vitro antibacterial activities of crude extracts of the leaves of Helichrysum longifolium in combination with selected antibiotics | |
| Magnet et al. | Isolation and identification of different bacteria from different types of burn wound infections and study their antimicrobial sensitivity pattern | |
| US20210361738A1 (en) | Bacteriophage-derived recombinant protein having antimicrobial activity against pathogenic gram-negative bacteria | |
| Maple et al. | Comparative in-vitro activity of vancomycin, teicoplanin, ramoplanin (formerly A16686), paldimycin, DuP 721 and DuP 105 against methicillin and gentamicin resistant Staphylococcus aureus | |
| Sofy et al. | Evaluation of Antibacterial and Antibiofilm Activity of New Antimicrobials as an Urgent Need to Counteract Stubborn Multidrug-resistant Bacteria. | |
| CN110251526A (zh) | 芍药苷在抑制耐碳青霉烯类肺炎克雷伯菌生长中的应用 | |
| TW200510541A (en) | Antibiotic 107891, its factors A1 and A2, pharmaceutically acceptable salts and compositions, and use thereof | |
| PL435199A1 (pl) | Kompozycja bakteriofagów specyficzna wobec bakterii z rodziny Enterobacterlaceae, zwłaszcza Escherichia coli, zastosowanie kompozycji bakteriofagów do leczenia zakażeń wywołanych przez bakterie z rodziny Enterobacterlaceae, zwłaszcza Escherichia coli oraz zastosowanie kompozycji bakteriofagów jako czynnika biokontroli | |
| EA202190206A1 (ru) | Антимикробная композиция против гастроинтестинальных инфекций и ее применение | |
| MX2022011291A (es) | Nueva lisina recombinante y su uso en el tratamiento de infecciones por bacterias gramnegativas. | |
| Karim et al. | Bacterial isolates in neutropenic febrile patients | |
| GEP20197029B (en) | Antimicrobial composition and the use of thereof | |
| Sharma et al. | Aerobic bacteriological profile of skin and soft tissue infections (SSTIs) and its antimicrobial susceptibility pattern at MB Govt. Hospital in Udaipur, Rajasthan. Education (ASME) | |
| CN110974838B (zh) | 金化合物在制备抗菌剂中的应用 | |
| Lanzafame et al. | In vitro activity of levofloxacin against recent Gram-negative nosocomial pathogens | |
| CN114617886A (zh) | 化合物及其药学上可接受的盐的抗菌用途 | |
| Selwyn et al. | In vitro and in vivo studies on antibiotics from skin micrococcaceae | |
| CN113262214A (zh) | 盐酸西那卡塞在制备抗菌药物中的应用 | |
| Gibson et al. | Trends in bacterial infections in febrile neutropenic patients: 1986–1992 | |
| Wali et al. | Fosfomycin Versus Nitrofurantoin Efficacy Against Multi-Drug Resistant Gram Negative Urinary Pathogens. | |
| Sklyar et al. | Resistance of nosocomial strains to antibacterial drugs and its link to biofilm formation | |
| PL430175A1 (pl) | Szczepy bakteriofagów specyficzne wobec bakterii Escherichia coli oraz ich zastosowanie do wytwarzania preparatów zwalczających bakterie patogenne | |
| Al-naimi et al. | Research article recurrent urinary tract infections in iraqi leukemic patients |